Ionis touts PhIII success for rare disease drug amid company's push to commercialize drugs independently
Ionis Pharmaceuticals’ hereditary angioedema treatment helped cut the rate of attacks associated with the rare genetic disease in a Phase III study.
People with hereditary …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
